Developer docs
API playgroundTry for free, no card

Search company profiles

Fimbrion Therapeutics

Full company profile

uuid000e3i4

Namestring
Fimbrion Therapeutics
Legal namestring
Fimbrion Therapeutics, Inc.
Websiteurl
fimbrion.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Fimbrion Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2012 and based in St. Louis, Missouri. The company develops antimicrobial-sparing therapeutics that target bacterial virulence mechanisms rather than bacterial viability, with the goal of treating and preventing infections while preserving the microbiome and mitigating antimicrobial resistance. Its core programs address two indications: recurrent and complicated urinary tract infections (UTIs) caused by uropathogenic E. coli, and tuberculosis including multidrug-resistant TB. Fimbrion operates with 1-10 employees and has no commercialized products.

The company's platform rests on mannoside-based FimH antagonists and heterocyclic QcrB inhibitors. The lead asset, GSK3882347, is an orally bioavailable mannose-containing small molecule that blocks the FimH adhesin, preventing uropathogenic E. coli from binding to bladder walls and enabling natural clearance; it entered Phase I clinical trials in 2020 under GlaxoSmithKline, which holds development and commercialization rights via a 2016 Discovery Partnerships with Academia (DPAc) collaboration. A complementary program includes FimH-targeting monoclonal antibodies and biologics for complicated UTIs. The tuberculosis program is built on QcrB inhibitors in-licensed from Saint Louis University and developed in the lab of co-founder Christina Stallings at Washington University, supported by NIH SBIR Phase I (2021) and Phase II (2024) awards. The company controls more than 40 US-granted patents across its co-founders and is led by an academic-scientist founding team with deep expertise in microbiology, medicinal chemistry, and infectious disease clinical practice.

Fimbrion's business model is pre-commercial and asset-centric: it generates no product revenue today and has not disclosed pricing for any future approved drug. Future revenue mechanics are described as licensing and royalties, with GSK effectively serving as the sole commercial counterparty for the lead asset. The company funds operations through a mix of non-dilutive sources, including NIH SBIR grants (Phase I and Phase II) and a $7.51 million CARB-X award directed to GSK for Phase I development of GSK3882347, alongside early-stage support from BioSTL/Biogenerator. Customer segments are defined by disease (recurrent UTI patients, complicated UTI patients, TB patients including MDR-TB) rather than direct B2B buyers, and distribution is anticipated to flow through GSK's global pharmaceutical network upon regulatory approval.

Short descriptiontext

Fimbrion Therapeutics is a St. Louis-based, clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs, including the Phase I FimH antagonist GSK3882347 partnered with GSK for recurrent UTIs and preclinical QcrB inhibitors for tuberculosis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial drug development, antivirulence therapeutics, urinary tract infection treatment, tuberculosis therapeutics, bacterial adhesion inhibitors
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeLicensing Royalties
Description

Pre-revenue biopharmaceutical company focused on drug discovery, development, and commercialization of novel antimicrobial-sparing therapeutics. No commercialized products yet.

fimbrion.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fimbrion Therapeutics is a clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs that target bacterial adhesion (FimH) and virulence (QcrB) mechanisms rather than bacterial viability. Its lead clinical asset GSK3882347, an oral mannoside FimH antagonist partnered with GSK, has entered Phase I trials for recurrent urinary tract infections, supported by a pipeline of QcrB inhibitors for tuberculosis and FimH-targeting monoclonal antibodies for complicated UTIs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase I clinical trials commenced for GSK3882347
+1 more record
Product overview1 text field

Fimbrion Therapeutics is developing a pipeline of antimicrobial-sparing antivirulence drugs targeting bacterial adhesion mechanisms rather than bacterial viability. The core portfolio includes GSK3882347, an oral mannoside FimH antagonist (Phase I clinical trials), QcrB inhibitors for tuberculosis (preclinical), and FimH-targeting monoclonal antibodies/biologics for complicated UTIs. The mannoside technology platform underlies the UTI program and was developed with NIH SBIR funding and licensed from Washington University.

Product and service3 records
1GSK3882347 (Mannoside FimH Antagonist)
CategoryInfectious disease therapeutics / Antiviral/Antibacterial small molecule
Description

Orally bioavailable mannose-containing small molecule that targets the FimH adhesive protein on uropathogenic E. coli, preventing the bacteria from sticking to bladder walls and enabling natural elimination of infection; intended for treatment and prevention of recurrent urinary tract infections. Entered Phase I clinical trials co-developed with GSK.

2QcrB Inhibitors (Tuberculosis Program)
CategoryInfectious disease therapeutics / Tuberculosis antibacterial
Description

Heterocyclic compounds with inhibitory and bactericidal activity against Mycobacterium tuberculosis, targeting the QcrB protein in the respiratory electron transport chain with low-nanomolar potency and a potentially superior resistance profile relative to clinical-stage comparator Q203. Developed for treatment of drug-sensitive and multidrug-resistant tuberculosis.

3FimH-Targeting Monoclonal Antibodies and Biologics
CategoryInfectious disease therapeutics / Biologics for complicated UTIs
Description

Monoclonal antibodies and biologics targeting the bacterial FimH adhesin, intended for use in patients with complicated urinary tract infections as an antibiotic-sparing, narrow-spectrum therapeutic approach.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-22
Description

GSK partnered with Fimbrion in 2016 through the Discovery Partnerships with Academia (DPAc) team to accelerate lead optimization efforts. The collaboration led to selection of GSK3882347 as a clinical candidate in 2018. CARB-X awarded $7.51 million to GSK for Phase I clinical development of this novel oral antibacterial therapy for UTIs, co-developed with Fimbrion. Fimbrion continues to actively support clinical development with ongoing preclinical research studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fimbrion was founded in 2012 from intellectual property licensed from Washington University School of Medicine. Mannoside technology originated in laboratories of co-founders Scott Hultgren and James Janetka at Washington University. Thomas Hannan maintains part-time faculty appointment at Washington University School of Medicine. Christina Stallings is also a professor at Washington University.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fimbrion in-licensed intellectual property for QcrB inhibitor series from Saint Louis University in addition to Washington University, for compounds targeting Mycobacterium tuberculosis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Iterum is developing sulopenem, an oral and IV antibacterial for uncomplicated and complicated UTIs caused by resistant pathogens. Like Fimbrion, it is a small-cap specialty antibacterial company focused squarely on the UTI market and faces the same regulatory, stewardship, and commercialization dynamics.

TypeEmerging player
Description

Cidara is developing antiviral and antifungal biologics, including its Cloudbreak antiviral-conjugate platform targeting serious infections. Its focus on immune-engaging anti-infective biologics makes it a relevant comparable for Fimbrion's FimH monoclonal antibody program and broader anti-infective biologics strategy.

TypeBroad incumbent
Description

Melinta commercialized delafloxacin (Baxdela) and the meropenem/vaborbactam combination (Vabomere), both antibacterials targeting drug-resistant infections. Like Fimbrion's target commercial environment, Melinta navigated the challenging economics of launching novel antibacterials in a stewardship-constrained market and ultimately underwent restructuring.

TypeBroad incumbent
Description

Entasis developed sulbactam-durlobactam (Xacduro) for Acinetobacter baumannii infections and was acquired by Innoviva. It is a directly comparable targeted antibacterial company whose portfolio focus on resistant Gram-negative infections mirrors Fimbrion's UTIs caused by uropathogenic E. coli.

5Nabriva Therapeutics
TypeBroad incumbent
Description

Nabriva developed and commercialized lefamulin (Xenleta), a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia. It is a small-cap specialty antibacterial company pursuing a comparable playbook of developing differentiated mechanism-of-action drugs against resistant pathogens.

TypeBroad incumbent
Description

Summit has developed ridinilazole for C. difficile infection and is investing in antibacterial and anti-infective development. While larger and more diversified, it operates in the same antibacterial development space and faces similar commercial challenges around novel-mechanism antibiotics.

TypeBroad incumbent
Description

Tetraphase developed eravacycline (Xerava), an IV fluorocycline antibiotic approved for complicated intra-abdominal infections. It is a directly comparable specialty antibacterial biotech that ultimately was acquired by La Jolla Pharmaceutical Company, illustrating the typical M&A exit path for this category.

TypeBroad incumbent
Description

Paratek developed and commercialized omadacycline (Nuzyra), a modern tetracycline antibiotic approved for community-acquired bacterial pneumonia and skin infections. It is a directly comparable specialty antibacterial company that has navigated FDA approval, commercialization, and ultimately an acquisition by Innoviva.

TypeEmerging player
Description

VenatoRx is a private anti-infective company developing both antibacterial and antiviral agents, including beta-lactamase inhibitor combinations targeting resistant pathogens. As a similarly sized private anti-infective biotech, it represents a relevant peer in stage, focus, and funding profile.

10Utility Therapeutics
TypeDirect peer
Description

Utility Therapeutics is developing pivmecillinam (an oral antibacterial) for uncomplicated UTIs in the US market. It is one of the closest pure-play UTI antibacterial comparables to Fimbrion's lead program and operates in the same regulatory and prescriber environment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fimbrion Therapeutics

Infectious Disease Therapeuticsfimbrion.com

Fimbrion Therapeutics is a St. Louis-based, clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs, including the Phase I FimH antagonist GSK3882347 partnered with GSK for recurrent UTIs and preclinical QcrB inhibitors for tuberculosis.

What Fimbrion Therapeutics does

Fimbrion Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2012 and based in St. Louis, Missouri. The company develops antimicrobial-sparing therapeutics that target bacterial virulence mechanisms rather than bacterial viability, with the goal of treating and preventing infections while preserving the microbiome and mitigating antimicrobial resistance. Its core programs address two indications: recurrent and complicated urinary tract infections (UTIs) caused by uropathogenic E. coli, and tuberculosis including multidrug-resistant TB. Fimbrion operates with 1-10 employees and has no commercialized products.

The company's platform rests on mannoside-based FimH antagonists and heterocyclic QcrB inhibitors. The lead asset, GSK3882347, is an orally bioavailable mannose-containing small molecule that blocks the FimH adhesin, preventing uropathogenic E. coli from binding to bladder walls and enabling natural clearance; it entered Phase I clinical trials in 2020 under GlaxoSmithKline, which holds development and commercialization rights via a 2016 Discovery Partnerships with Academia (DPAc) collaboration. A complementary program includes FimH-targeting monoclonal antibodies and biologics for complicated UTIs. The tuberculosis program is built on QcrB inhibitors in-licensed from Saint Louis University and developed in the lab of co-founder Christina Stallings at Washington University, supported by NIH SBIR Phase I (2021) and Phase II (2024) awards. The company controls more than 40 US-granted patents across its co-founders and is led by an academic-scientist founding team with deep expertise in microbiology, medicinal chemistry, and infectious disease clinical practice.

Fimbrion's business model is pre-commercial and asset-centric: it generates no product revenue today and has not disclosed pricing for any future approved drug. Future revenue mechanics are described as licensing and royalties, with GSK effectively serving as the sole commercial counterparty for the lead asset. The company funds operations through a mix of non-dilutive sources, including NIH SBIR grants (Phase I and Phase II) and a $7.51 million CARB-X award directed to GSK for Phase I development of GSK3882347, alongside early-stage support from BioSTL/Biogenerator. Customer segments are defined by disease (recurrent UTI patients, complicated UTI patients, TB patients including MDR-TB) rather than direct B2B buyers, and distribution is anticipated to flow through GSK's global pharmaceutical network upon regulatory approval.

Fimbrion Therapeutics firmographics

Firmographics
Name
Fimbrion Therapeutics
Legal name
Fimbrion Therapeutics, Inc.
Website
https://fimbrion.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Fimbrion Therapeutics is a St. Louis-based, clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs, including the Phase I FimH antagonist GSK3882347 partnered with GSK for recurrent UTIs and preclinical QcrB inhibitors for tuberculosis.
Ownership category
akta.pro rank

Where Fimbrion Therapeutics is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Fimbrion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: Pre-revenue biopharmaceutical company focused on drug discovery, development, and commercialization of novel antimicrobial-sparing therapeutics. No commercialized products yet.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Fimbrion Therapeutics product offering

Product offering

Core offering

Fimbrion Therapeutics is a clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs that target bacterial adhesion (FimH) and virulence (QcrB) mechanisms rather than bacterial viability. Its lead clinical asset GSK3882347, an oral mannoside FimH antagonist partnered with GSK, has entered Phase I trials for recurrent urinary tract infections, supported by a pipeline of QcrB inhibitors for tuberculosis and FimH-targeting monoclonal antibodies for complicated UTIs.

Product overview

Fimbrion Therapeutics is developing a pipeline of antimicrobial-sparing antivirulence drugs targeting bacterial adhesion mechanisms rather than bacterial viability. The core portfolio includes GSK3882347, an oral mannoside FimH antagonist (Phase I clinical trials), QcrB inhibitors for tuberculosis (preclinical), and FimH-targeting monoclonal antibodies/biologics for complicated UTIs. The mannoside technology platform underlies the UTI program and was developed with NIH SBIR funding and licensed from Washington University.

Differentiator

Problem solved

Functional benefit

Products and services

  • GSK3882347 (Mannoside FimH Antagonist) Orally bioavailable mannose-containing small molecule that targets the FimH adhesive protein on uropathogenic E. coli, preventing the bacteria from sticking to bladder walls and enabling natural elimination of infection; intended for treatment and prevention of recurrent urinary tract infections. Entered Phase I clinical trials co-developed with GSK.
  • QcrB Inhibitors (Tuberculosis Program) Heterocyclic compounds with inhibitory and bactericidal activity against Mycobacterium tuberculosis, targeting the QcrB protein in the respiratory electron transport chain with low-nanomolar potency and a potentially superior resistance profile relative to clinical-stage comparator Q203. Developed for treatment of drug-sensitive and multidrug-resistant tuberculosis.
  • FimH-Targeting Monoclonal Antibodies and Biologics Monoclonal antibodies and biologics targeting the bacterial FimH adhesin, intended for use in patients with complicated urinary tract infections as an antibiotic-sparing, narrow-spectrum therapeutic approach.

Quantifiable outcome

  • Phase I clinical trials commenced for GSK3882347
  • +1 more outcomes

Companies that use Fimbrion Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Fimbrion Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Fimbrion Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 22 September 2020GSK partnered with Fimbrion in 2016 through the Discovery Partnerships with Academia (DPAc) team to accelerate lead optimization efforts. The collaboration led to selection of GSK3882347 as a clinical candidate in 2018. CARB-X awarded $7.51 million to GSK for Phase I clinical development of this novel oral antibacterial therapy for UTIs, co-developed with Fimbrion. Fimbrion continues to actively support clinical development with ongoing preclinical research studies.
  • Washington University in St. LouiscoreStrategic or Co-development PartnerFimbrion was founded in 2012 from intellectual property licensed from Washington University School of Medicine. Mannoside technology originated in laboratories of co-founders Scott Hultgren and James Janetka at Washington University. Thomas Hannan maintains part-time faculty appointment at Washington University School of Medicine. Christina Stallings is also a professor at Washington University.
  • Saint Louis UniversityminorStrategic or Co-development PartnerFimbrion in-licensed intellectual property for QcrB inhibitor series from Saint Louis University in addition to Washington University, for compounds targeting Mycobacterium tuberculosis.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Fimbrion Therapeutics competitors and assessment

Company assessment

Direct peers

  • Iterum Therapeutics: Iterum is developing sulopenem, an oral and IV antibacterial for uncomplicated and complicated UTIs caused by resistant pathogens. Like Fimbrion, it is a small-cap specialty antibacterial company focused squarely on the UTI market and faces the same regulatory, stewardship, and commercialization dynamics.
  • Utility Therapeutics: Utility Therapeutics is developing pivmecillinam (an oral antibacterial) for uncomplicated UTIs in the US market. It is one of the closest pure-play UTI antibacterial comparables to Fimbrion's lead program and operates in the same regulatory and prescriber environment.

Emerging players

  • Cidara Therapeutics: Cidara is developing antiviral and antifungal biologics, including its Cloudbreak antiviral-conjugate platform targeting serious infections. Its focus on immune-engaging anti-infective biologics makes it a relevant comparable for Fimbrion's FimH monoclonal antibody program and broader anti-infective biologics strategy.
  • VenatoRx Pharmaceuticals: VenatoRx is a private anti-infective company developing both antibacterial and antiviral agents, including beta-lactamase inhibitor combinations targeting resistant pathogens. As a similarly sized private anti-infective biotech, it represents a relevant peer in stage, focus, and funding profile.

Broad incumbents

  • Melinta Therapeutics: Melinta commercialized delafloxacin (Baxdela) and the meropenem/vaborbactam combination (Vabomere), both antibacterials targeting drug-resistant infections. Like Fimbrion's target commercial environment, Melinta navigated the challenging economics of launching novel antibacterials in a stewardship-constrained market and ultimately underwent restructuring.
  • Entasis Therapeutics: Entasis developed sulbactam-durlobactam (Xacduro) for Acinetobacter baumannii infections and was acquired by Innoviva. It is a directly comparable targeted antibacterial company whose portfolio focus on resistant Gram-negative infections mirrors Fimbrion's UTIs caused by uropathogenic E. coli.
  • Nabriva Therapeutics: Nabriva developed and commercialized lefamulin (Xenleta), a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia. It is a small-cap specialty antibacterial company pursuing a comparable playbook of developing differentiated mechanism-of-action drugs against resistant pathogens.
  • Summit Therapeutics: Summit has developed ridinilazole for C. difficile infection and is investing in antibacterial and anti-infective development. While larger and more diversified, it operates in the same antibacterial development space and faces similar commercial challenges around novel-mechanism antibiotics.
  • Tetraphase Biosciences: Tetraphase developed eravacycline (Xerava), an IV fluorocycline antibiotic approved for complicated intra-abdominal infections. It is a directly comparable specialty antibacterial biotech that ultimately was acquired by La Jolla Pharmaceutical Company, illustrating the typical M&A exit path for this category.
  • Paratek Pharmaceuticals: Paratek developed and commercialized omadacycline (Nuzyra), a modern tetracycline antibiotic approved for community-acquired bacterial pneumonia and skin infections. It is a directly comparable specialty antibacterial company that has navigated FDA approval, commercialization, and ultimately an acquisition by Innoviva.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Fimbrion Therapeutics social profiles

Digital presence

Fimbrion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fimbrion Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Fimbrion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fimbrion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fimbrion Therapeutics

What does Fimbrion Therapeutics do?

Fimbrion Therapeutics is a clinical-stage biopharmaceutical company developing antimicrobial-sparing antivirulence drugs that target bacterial adhesion (FimH) and virulence (QcrB) mechanisms rather than bacterial viability. Its lead clinical asset GSK3882347, an oral mannoside FimH antagonist partnered with GSK, has entered Phase I trials for recurrent urinary tract infections, supported by a pipeline of QcrB inhibitors for tuberculosis and FimH-targeting monoclonal antibodies for complicated UTIs.

Is Fimbrion Therapeutics a public or private company?

Fimbrion Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Fimbrion Therapeutics founded?

Fimbrion Therapeutics was founded in 2012. It employs 1 to 10 people.

Where is Fimbrion Therapeutics based?

Fimbrion Therapeutics is headquartered in St Louis, United States, in the North America region.

How does Fimbrion Therapeutics make money?

One revenue line is on record: pharmaceutical Development.

Who are Fimbrion Therapeutics's main competitors?

Direct peers on record are Iterum Therapeutics and Utility Therapeutics. Emerging players are Cidara Therapeutics and VenatoRx Pharmaceuticals. Broad incumbents are Melinta Therapeutics, Entasis Therapeutics, Nabriva Therapeutics, Summit Therapeutics, Tetraphase Biosciences and Paratek Pharmaceuticals.

Does Fimbrion Therapeutics have an API?

No public API is recorded for Fimbrion Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFimbrion y GSK descubren un posible fármaco novedoso para el tratamiento de las infecciones urinariasFimbrion Therapeutics announced alongside GSK the discovery of an oral micromolecule with clinical development potential for treating and preventing urinary tract infections (UTIs), developed through their research collaboration initiated in July 2016. The compound targets the FimH adhesive protein in bacteria, preventing attachment to bladder walls and enabling natural infection clearance without destroying bacteria, which could avoid triggering antibiotic resistance. The discovery represents a novel antimicrobial strategy addressing a growing health concern, with over 20 million UTI cases annually in the United States.PR NewswireFimbrion et GSK identifient un nouveau candidat au développement permettant d'éviter le recours aux antibiotiques pour le traitement des infections du tractus urinaireFimbrion Therapeutics and GSK announced that their joint research, initiated in July 2016, has identified a new oral small molecule drug candidate containing mannose for treating and preventing urinary tract infections.PR NewswireFimbrion and GSK Identify Novel, Antibiotic-Sparing Development Candidate for Urinary Tract InfectionsFimbrion Therapeutics and GSK announced the identification of an orally available, small molecule development candidate for treating and preventing urinary tract infections under their joint research collaboration that began in July 2016. The novel drug targets the FimH adhesive protein in bacteria, preventing UTI-causing bacteria from sticking to bladder walls so the body can naturally eliminate the infection, offering a potential antibiotic-sparing approach. More than 20 million UTIs occur annually in the US, where antibiotic resistance has increasingly limited treatment options for gram-negative bacterial infections.PR NewswireFimbrion and GSK to Develop Novel Antibacterial Therapy for Urinary Tract InfectionsFimbrion Therapeutics entered into a collaboration with GlaxoSmithKline to jointly develop a small molecule drug based on mannoside compounds for the treatment and prevention of urinary tract infections. The partnership combines Fimbrion's disease expertise and mannoside discovery platform with GSK's drug discovery and development capabilities, with the project focused on preclinical development. Mannosides represent a novel antibiotic-sparing approach that could treat UTIs without inducing antibiotic resistance, addressing a growing clinical need as resistance to conventional therapies increases.PR NewswireFimbrion y GSK desarrollarán innovadora terapia antibacteriana para infecciones de las vías urinariasFimbrion Therapeutics and GlaxoSmithKline announced a collaboration to jointly develop mannoside compounds for treating and preventing urinary tract infections without causing antibiotic resistance. The partnership combines Fimbrion's expertise in antivirulent drug design with GSK's drug discovery and development capabilities through GSK's Discovery Partnerships with Academia (DPAc) team. Mannosides work by preventing bacteria from adhering to bladder walls, offering a novel approach to combat the growing prevalence of drug-resistant bacterial infections.